Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

telisotuzumab vedotin (ABBV-399)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

AbbVie

Drug class:

Microtubule inhibitor, c-MET-targeted antibody-drug conjugate

Related drugs:

‹

HRA00129-C004 (3)

REGN5093-M114 (3)

ado-trastuzumab emtansine (97)

eribulin mesylate (47)

brentuximab vedotin (29)

disitamab vedotin (27)

mirvetuximab soravtansine-gynx (16)

enfortumab vedotin-ejfv (14)

cabazitaxel (12)

ixabepilone (6)

LR004-VC-MMAE (5)

PF-06804103 (4)

PF-08046048 (4)

PF-08046047 (4)

belantamab mafodotin-blmf (3)

polatuzumab vedotin-piiq (3)

RGX-019-MMAE (3)

BAY 94-9343 (3)

IMAB027-vcMMAE (2)

PF-06650808 (2)

MF-TTZ-MMAE (1)

PF-06263507 (1)

PF-08046054 (1)

tisotumab vedotin-tftv (1)

estramustine (0)

Nectin-4 ADC (0)

vintafolide (0)

HuMax-AXL-ADC (0)

mebendazole (0)

HRA00129-C004 (3)

REGN5093-M114 (3)

›

EGFR wild-type + MET overexpression	Lung Non-Squamous Non-Small Cell Cancer	EGFR wild-type + MET overexpression	Lung Non-Squamous Non-Small Cell Cancer	ABBV-399 Sensitive: B - Late Trials ABBV-399 Sensitive : B	ABBV-399 Sensitive: B - Late Trials ABBV-399 Sensitive : B
EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	erlotinib + ABBV-399 Sensitive: C2 – Inclusion Criteria erlotinib + ABBV-399 Sensitive : C2	erlotinib + ABBV-399 Sensitive: C2 – Inclusion Criteria erlotinib + ABBV-399 Sensitive : C2
MET positive	Non Small Cell Lung Cancer	MET positive	Non Small Cell Lung Cancer	ABBV-399 Sensitive: C2 – Inclusion Criteria ABBV-399 Sensitive : C2	ABBV-399 Sensitive: C2 – Inclusion Criteria ABBV-399 Sensitive : C2
MET overexpression	Lung Non-Squamous Non-Small Cell Cancer	MET overexpression	Lung Non-Squamous Non-Small Cell Cancer	ABBV-399 Sensitive: C2 – Inclusion Criteria ABBV-399 Sensitive : C2	ABBV-399 Sensitive: C2 – Inclusion Criteria ABBV-399 Sensitive : C2
MET positive	Lung Non-Squamous Non-Small Cell Cancer	MET positive	Lung Non-Squamous Non-Small Cell Cancer	erlotinib + ABBV-399 Sensitive: C3 – Early Trials erlotinib + ABBV-399 Sensitive : C3	erlotinib + ABBV-399 Sensitive: C3 – Early Trials erlotinib + ABBV-399 Sensitive : C3
MET positive	Lung Non-Small Cell Squamous Cancer	MET positive	Lung Non-Small Cell Squamous Cancer	erlotinib + ABBV-399 Sensitive: C3 – Early Trials erlotinib + ABBV-399 Sensitive : C3	erlotinib + ABBV-399 Sensitive: C3 – Early Trials erlotinib + ABBV-399 Sensitive : C3
EGFR mutation	Lung Non-Small Cell Squamous Cancer	EGFR mutation	Lung Non-Small Cell Squamous Cancer	erlotinib + ABBV-399 Sensitive: C3 – Early Trials erlotinib + ABBV-399 Sensitive : C3	erlotinib + ABBV-399 Sensitive: C3 – Early Trials erlotinib + ABBV-399 Sensitive : C3
MET overexpression + EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	MET overexpression + EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	ABBV-399 Sensitive: C3 – Early Trials ABBV-399 Sensitive : C3	ABBV-399 Sensitive: C3 – Early Trials ABBV-399 Sensitive : C3
MET overexpression + EGFR mutation	Non Small Cell Lung Cancer	MET overexpression + EGFR mutation	Non Small Cell Lung Cancer	osimertinib + ABBV-399 Sensitive: C3 – Early Trials osimertinib + ABBV-399 Sensitive : C3	osimertinib + ABBV-399 Sensitive: C3 – Early Trials osimertinib + ABBV-399 Sensitive : C3
MET overexpression + EGFR mutation	Non Small Cell Lung Cancer	MET overexpression + EGFR mutation	Non Small Cell Lung Cancer	erlotinib + ABBV-399 Sensitive: C3 – Early Trials erlotinib + ABBV-399 Sensitive : C3	erlotinib + ABBV-399 Sensitive: C3 – Early Trials erlotinib + ABBV-399 Sensitive : C3
EGFR mutation + MET overexpression	Non Small Cell Lung Cancer	EGFR mutation + MET overexpression	Non Small Cell Lung Cancer	osimertinib + ABBV-399 Sensitive: C3 – Early Trials osimertinib + ABBV-399 Sensitive : C3	osimertinib + ABBV-399 Sensitive: C3 – Early Trials osimertinib + ABBV-399 Sensitive : C3